VRTX vs. AMGN, REGN, GILD, AGN, ALXN, BIIB, ALNY, RPRX, BMRN, and BGNE
Should you be buying Vertex Pharmaceuticals stock or one of its competitors? The main competitors of Vertex Pharmaceuticals include Amgen (AMGN), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD), Allergan (AGN), Alexion Pharmaceuticals (ALXN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), and BeiGene (BGNE).
Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends.
In the previous week, Vertex Pharmaceuticals had 8 more articles in the media than Amgen. MarketBeat recorded 27 mentions for Vertex Pharmaceuticals and 19 mentions for Amgen. Amgen's average media sentiment score of 0.86 beat Vertex Pharmaceuticals' score of 0.82 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.
76.5% of Amgen shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.7% of Amgen shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Amgen has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.
Vertex Pharmaceuticals has a net margin of 39.46% compared to Vertex Pharmaceuticals' net margin of 12.74%. Vertex Pharmaceuticals' return on equity of 156.21% beat Amgen's return on equity.
Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
Amgen currently has a consensus price target of $305.65, suggesting a potential upside of 0.31%. Vertex Pharmaceuticals has a consensus price target of $438.62, suggesting a potential downside of 9.24%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Amgen is more favorable than Vertex Pharmaceuticals.
Vertex Pharmaceuticals received 30 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 75.63% of users gave Vertex Pharmaceuticals an outperform vote while only 72.41% of users gave Amgen an outperform vote.
Summary
Vertex Pharmaceuticals beats Amgen on 10 of the 18 factors compared between the two stocks.
Get Vertex Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vertex Pharmaceuticals Competitors List
Related Companies and Tools
